scPharmaceuticals Inc.
SCPH · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.35 | 0.15 | 0.05 | -0.02 |
| FCF Yield | -7.87% | -12.14% | -9.64% | -8.21% |
| EV / EBITDA | -15.13 | -7.66 | -7.78 | -5.21 |
| Quality | ||||
| ROIC | -23.79% | -23.71% | -17.59% | -16.46% |
| Gross Margin | 68.76% | 70.46% | 67.37% | 66.98% |
| Cash Conversion Ratio | 0.89 | 0.87 | 0.81 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | 138.12% | 173.02% | 3,311,946.57% | 3,116,700.91% |
| Free Cash Flow Growth | 6.00% | -12.77% | 12.82% | 13.81% |
| Safety | ||||
| Net Debt / EBITDA | -0.81 | 0.29 | 1.33 | 1.17 |
| Interest Coverage | -10.20 | -12.82 | -11.01 | -9.81 |
| Efficiency | ||||
| Inventory Turnover | 0.34 | 0.25 | 0.29 | 0.18 |
| Cash Conversion Cycle | 298.33 | 343.43 | 314.26 | 438.93 |